Stock listing

NASDAQ:PRAX Praxis Precision Medicines, Inc. Stock

Home listing (NASDAQ) of Praxis Precision Medicines, Inc.

Follow Praxis Precision Medicines, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PRAX

$241.76 USD -6.48 (-2.6%)

Close on Oct 16, 2026

Since Jul 6, 2026 -22.9% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$241.76 – $251.78 USDOct 16, 2026
Volume
502,610 sharesOct 16, 2026
Market value
$6.75B USDAt the close on Oct 16, 2026 · price × 27.92M shares outstanding
Praxis Precision Medicines, Inc. logo
Ticker
NASDAQ:PRAX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Praxis Precision Medicines (NASDAQ:PRAX) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:30 AM ET

    Watch Transcript

  • Praxis Precision Medicines (NASDAQ:PRAX) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:30 AM ET

    Watch Transcript

  • Praxis Precision Medicines (NASDAQ:PRAX) Q4 2025 Earnings Call

    Thu, Feb 19, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2026

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Jul 30, 2026

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Jul 7, 2026

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Jun 29, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Jun 22, 2026

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Jun 4, 2026

Praxis Precision Medicines Provides Vormatrigine Program Update

Jun 1, 2026

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

May 4, 2026

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Apr 14, 2026

All Praxis Precision Medicines, Inc. news

Decks

Praxis Precision Medicines, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 157 in all · newest Oct 2, 2026 · oldest 2020
Calls
9 calls with a replay · 9 with a transcript · latest Aug 6, 2026
Decks
34 decks · latest September 2026

Where Praxis Precision Medicines, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PRAX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PRAXBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Praxis Precision Medicines, Inc.